Community-acquired pneumonia against a background of chronic heart failure: diagnosis and treatment

Community-acquired pneumonia is one of the most common infectious diseases in developed countries. Chronic heart failure is an independent risk factor for unfavorable course and prognosis of community-acquired pneumonia. Objective challenges of clinical, radiological, laboratory and microbiological diagnosis of community-acquired pneumonia in elderly patients with chronic heart failure dictate the need for a greater number of physicians to routinely examine for serum biomarkers of inflammation. Systemic antibiotic therapy for the category of patients is carried out in accordance with the standard guidelines and should be based on certain peculiarities of the etiology, impact of concomitant functional impairment of the organ systems and additional medication therapy on the pharmacokinetics of antimicrobial agents, and take into account the risk of potentiation of adverse reactions as a result of administration of drugs.

внебольничная пневмония, инфекции нижних дыхательных путей, хроническая сердечная недостаточность, диагностика, лечение, антибактериальная терапия, фторхинолоны, левофлоксацин, моксифлоксацин, community-acquired pneumonia, lower respiratory tract infections, chronic heart failure, diagnosis, treatment, antibiotic therapy, fluoroquinolones, levofloxacin, moxifloxacin

1. Trotter CL, Stuart JM, George R et al. Increasing hospital admissions for pneumonia, England. EmergInfectDis, 2008, 14: 727-33.

2. Чучалин А.Г Клинические рекомендации. Пульмонология. М.: ГЭОТАР-Медиа, 2005.

3. Чучалин А.Г Респираторная медицина. М.: ГЭОТАР-Медиа, 2007.

4. Torres A, Peetermans WE, Viegi G et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax., 2013, 68(11): 1057-65.

5. Brown JS. Community-acquired pneumonia. Clin Med., 2012, 12(6): 538-43.

6. Steel HC, Cockeran R, Anderson R et al. Overview of Community-Acquired Pneumonia and the Role of Inflammatory Mechanisms in the Immunopathogenesis of Severe Pneumococcal Disease. Mediators Inflamm., 2013, 2013: 490346.

7. Gau J, Acharya U, Khan S et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatrics, 2010, 10: 45.

8. Sopena N, Pedro-Botet L, Mateu L et al. Community-acquired legionella pneumonia in elderly patients: characteristics and outcome. J Am Geriatr Soc., 2007, 55(1): 114-9.

9. Thomsen RW, Riis A, Norgaard M et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med., 2006, 259: 410-7.

10. Corrales-Medina VF, Musher DM, Wells GA. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation, 2012, 125(6): 773-81.

11. Kondo A, Morinaga Y, Sasaki E et al. Prognostic and risk factors in patients hospitalized with bacterial pneumonia. Kansenshogaku Zasshi., 2007, 81(3): 268-75.

12. Welte T. Community-acquired pneumonia. Internist (Berl), 2009, 50(3): 331-9.

13. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med,, 2009, 30(2): 127-35.

14. Fujiki R, Kawayama T, Ueyama T et al. The risk factors for mortality of community-acquired pneumonia in Japan. J Infect Chemother., 2007, 13(3): 157-65.

15. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N. Engl. J. Med., 1997, 336: 243-250.

16. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax., 2003, 58: 377-382.

17. Liu L. Changes in cardiovascular hospitalization and comorbidity of heart failure in the United States: findings from the National Hospital Discharge Surveys 1980-2006. Int J Cardiol., 2011, 149(1): 39-45.

18. Dai S, Walsh P, Wielgosz A et al. Comorbidities and mortality associated with hospitalized heart failure in Canada. Can J Cardiol, 2012, 28(1): 74-9.

19. Pei ZY, Zhao YS, Li JY et al. Fifteen-year evolving trends of etiology and prognosis in hospitalized patients with heart failure. Zhonghua Xin Xue Guan BingZa Zhi, 2011, 39(5): 434-9.

20. Viasus D, Garcia-Vidal C, Manresa F et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect, 2013, 66(1): 27-33.

21. Musher DM, Rueda AM, Kaka AS et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis, 2007, 45(2): 158-65.

22. Чучалин А.Г, Синопальников А.И., Козлов РС. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клинмикробиол антимикробхимиотер, 2010, 12(3): 186-226.

23. Maisel A, Neath SX, Landsberg J et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail., 2012, 14(3): 278-86.

24. Dickstein K, CohenSolal A, Filippatos G et al. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J., 2008, 29: 2388-2442.

25. American Thoracic Society. ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med, 2002, 166: 111-117.